Nuwellis Inc vs Progressive Corp — how do they compare? Nuwellis Inc trades at $0.8 (market cap $2.50M), while Progressive Corp trades at $216.3 (market cap $124.88B). The key difference: Progressive Corp is far larger — about 49952× Nuwellis Inc's market cap, and Progressive Corp pays a 0.19% dividend while Nuwellis Inc pays none. Which is the better fit depends on your goals.
| NUWE | PGR | |
|---|---|---|
Market Cap | $2.50M | $124.88B |
Sector | Technology | Financials |
52-Week High | $164.50 | $248.80 |
52-Week Low | $0.73 | $190.40 |
Enterprise Value | -$1.21M | $133.09B |
Dividend Yield | — | 0.19% |
Signals from Pluang's Aura AI — not financial advice
NUWE trades at $0.7878, up 0.88% today, but remains in a bearish technical trend. The company shows strong gross margins of 69.69% and double-digit revenue growth, but faces significant profitability challenges with negative net income margins and ROE. Recent developments include a reverse stock split, new CEO appointment, and strategic partnerships expanding pediatric care footprint.
While NUWE demonstrates operational progress with revenue growth and margin improvement, persistent losses and negative cash flow present substantial risk. The mixed analyst sentiment and bearish technical indicators suggest cautious approach. Investment appeal hinges on successful execution of financial efficiency strategy and path to profitability.
Progressive (PGR) trades at $214.90, down 1.85% on the day, with a bearish technical signal and neutral oscillators. The stock shows strong fundamentals with a P/E of 10.78, net income margin of 12.85%, and consistent revenue growth from $49.6B in 2022 to $87.6B in 2025. Recent earnings beat expectations in Q2 2026, but Q1 2026 missed. News highlights competition in auto insurance and institutional buying, while July 2026 earnings declined year-over-year due to expenses.
The outlook is mixed: valuation appears attractive with growth potential, but technical weakness and competitive pressures pose risks. Analyst consensus is a buy with a $231.18 price target, though hold ratings dominate at 52.38%. Key risks include expense management and market volatility, while institutional accumulation supports sentiment.
Trailing returns across standard periods
Nuwellis, Inc. is a medical device company focused on developing and commercializing fluid management solutions. The company's primary product is an ultrafiltration system used in hospitals to remove excess fluid from patients with fluid overload, often associated with conditions such as heart and kidney failure. Nuwellis aims to improve patient outcomes and reduce healthcare costs through its specialized, innovative therapies.
Read more on NUWE →Progressive underwrites private and commercial auto insurance and specialty lines
Read more on PGR →